MYOV Insider Trading Activity and SEC Form 4 Filings
MYOV insider trading summary
No open-market insider purchases or sales of Myovant Sciences Ltd. (MYOV) have been reported on SEC Form 4 in the past 12 months.
Latest MYOV insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 10, 2023 | Sumitomo Pharma Co., Ltd. | 10% Owner | Buy | $1.39B (51,599,200 @ $27.00) |
| Mar 10, 2023 | Sumitovant Biopharma Ltd. | 10% Owner | Buy | $1.39B (51,599,200 @ $27.00) |
| Mar 10, 2023 | Sumitomo Chemical Co., Ltd. | 10% Owner | Buy | $1.39B (51,599,200 @ $27.00) |
| Jan 18, 2023 | Lauren Merendino | Chief Commercial Officer | Sell | $54K (2,008 @ $26.89) |
| Jan 18, 2023 | David C Marek | Principal Executive Officer | Sell | $216K (8,037 @ $26.89) |
| Jan 18, 2023 | Matthew Lang | General Counsel & Corp. Secy. | Sell | $34K (1,272 @ $26.89) |
| Jan 18, 2023 | Ferreira Juan Camilo Arjona | Chief Medical Officer | Sell | $30K (1,109 @ $26.89) |
| Jan 4, 2023 | Ferreira Juan Camilo Arjona | Chief Medical Officer | Sell | $61K (2,251 @ $26.90) |
| Jan 4, 2023 | Matthew Lang | General Counsel & Corp. Secy. | Sell | $75K (2,779 @ $26.90) |
| Dec 16, 2022 | Uneek Mehra | Principal Financial Officer | Sell | $60K (2,241 @ $26.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.